Industry

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

Collaboration extension through 2029 accelerates access to MRD technology across four major cancer types FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL) today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), adding a new indication, colorectal cancer (CRC), to the existing, exclusive commercialization agreement. The update means Personalis and Tempus … [Read more…]

SINOVAC Board of Directors Strongly Denounces Deceptive and Illegal Claims by SAIF and the Imposter Former Board

Special Meeting was validly adjourned until the appropriate court can make a final decision on the validity of the PIPE shares SAIF’s “announcement” about voting results demonstrates blatant disregard for the law and the Company’s bylaws and a repeated pattern of self-serving and unlawful actions by the Imposter Former Board Current Board remains the only … [Read more…]

VISIE Executes First Pin-Free Knee Bone Cuts Using Spatial Computing

No manual registration, pins, clamps or arrays AUSTIN, Texas–(BUSINESS WIRE)–VISIE Inc., the spatial computing company delivering the intelligence layer for surgical navigation and robotics, today announced a major technical milestone: the successful execution of all total knee arthroplasty (TKA) bone resections on cadaveric tissue, without the use of pins, clamps, arrays, or manual registration (Warning: … [Read more…]

LEO Pharma Announces Positive 16-Week Interim Results for ADHAND Trial for Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis on the Hands who are Candidates for Systemic Therapy

ADHAND is a phase 3b placebo-controlled clinical trial evaluating the efficacy and safety of tralokinumab in adult patients living with moderate-to-severe atopic dermatitis on the hands who are candidates for systemic therapy.1 The 16-week interim results of the ADHAND trial met the primary and all key secondary endpoints, showing statistically significant results compared to placebo. … [Read more…]

World First: CorWave’s Undulating Membrane Heart Pump Implanted in First Patient

First-of-its-kind heart pump implanted in Australia, based on a breakthrough wave membrane technology. Unlike existing devices, CorWave’s technology does not eliminate the effects of the native heartbeat and preserves the natural heart pulse. Early results suggest the pulsatility is preserved which could lead to a reduction of adverse events. The patient, suffering from advanced heart … [Read more…]

Bonerge Initiates Clinical Trial on Urolithin A and Fisetin for Sleep & Wellbeing

NEW YORK–(BUSINESS WIRE)–In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating the effects of Urolithin A and Fisetin on sleep quality, targeting sleep disorders through the lens of ageing biology. This randomized, quadruple-blind (participants, healthcare providers, researchers, assessors), placebo-controlled study will enroll over 80 participants aged 45-70. They will be divided into four groups: … [Read more…]

Preceptis Medical Appoints Dave Carey as Chief Executive Officer to Lead Next Phase of Strategic Growth

MINNEAPOLIS–(BUSINESS WIRE)–Preceptis Medical, Inc., a commercial-stage medical technology company transforming pediatric ENT care, today announced the appointment of Dave Carey as Chief Executive Officer. Carey assumes leadership as the company accelerates toward full market release of its flagship product, the Hummingbird® Tympanostomy Tube System (TTS). “We are thrilled to welcome Dave Carey to Preceptis,” said … [Read more…]

Avvio Medical’s Microbubble Technology Reduces Complications and Shows Promise for Enhancing Laser Lithotripsy: AEROLITH Trial Results Published in The Journal of Urology

SAN FRANCISCO–(BUSINESS WIRE)–Avvio Medical Inc. today announced the publication of its AEROLITH randomized clinical trial in The Journal of Urology. Study highlights were presented at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. The AEROLITH study evaluated the safety and effectiveness of Acoustic Enhancer Microbubble Cavitation (AEMC) when used with ureteroscopic … [Read more…]

Vertex to Announce Second Quarter 2025 Financial Results on August 4th

BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex … [Read more…]

The Ngāi Tahu Research Centre Has Entered Into a Strategic Partnership With De-Extinction Company, Colossal Biosciences, and Sir Peter Jackson, to Resurrect the South Island Giant Moa and Other Taonga Species

The Ngāi Tahu Research Centre coordinated project aims to advance ecological restoration and develop tools for conservation in Te Waipounamu, New Zealand’s South Island TE WAIPOUNAMU/SOUTH ISLAND, New Zealand–(BUSINESS WIRE)–In a historic indigenous-coordinated initiative, the Ngāi Tahu Research Centre has entered into a collaboration with Colossal Biosciences, a Texas-based genetic engineering and de-extinction company, and … [Read more…]